Details:
Beckley Psytech will use the proceeds to complete the ongoing Phase 1b trial with low-dose psilocybin in patients suffering from SUNHA. The funding will also support the expansion of the company’s pipeline with new, unique and proprietary psychedelic compounds.
Lead Product(s): Psilocybine
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Integrated
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 16, 2021